TSKU and systemic sclerosis: Treatment with AM1125 at 50 mg/kg reduced fibrosis parameters (hypodermal thickness, myofibroblast counts, and hydroxyproline content) in the tsk-1 model of SSc, which indicated a potential treatment opportunity for SSc.